All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
When should we consider allo-HSCT in a patient with ALL? And when not?
Bookmark this article
During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL. We asked, When should we consider allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a patient with ALL? And when not?
When should we consider allo-HSCT in a patient with ALL? And when not?
Allo-HSCT is a very effective method of treatment for ALL, however, it is also associated with a significant risk of mortality. In this video, Giebel discusses tailoring treatment paradigms according to Philadelphia chromosome subtypes and high-risk karyotypes. He also touches upon ongoing studies looking at second- or third-generation tyrosine kinase inhibitors and chimeric antigen receptor (CAR) T-cell therapies that could offer new opportunities for patients with ALL in the future.
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox